AQR Capital Management
BCLI

AQR Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

AQR Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,308
Closed -$89K – 2194
2020
Q4 		$89K Sell
1,308
-59
-4% -$8.04K ﹤0.01% 2158
2020
Q3 		$347K Buy
+1,367
New +$280K ﹤0.01% 1865

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

AQR Capital Management's BCLI Position: Q1 2021 in Review

AQR Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2021, closing a stake of 1,308 shares — an estimated $89K sold.

AQR Capital Management first reported a position in BCLI in Q3 2020 and held it in 2 quarters. The position peaked at $347K in Q3 2020. 75 funds tracked by Wall St. Rank hold BCLI as of Q1 2021.

  • AQR Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2021 after selling out during the quarter.
  • AQR Capital Management sold 1,308 BRAINSTORM CELL THERAPUTC shares in Q1 2021, an estimated $89K.
  • AQR Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2020 and held it in 2 quarters.
  • AQR Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $347K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2021.

Based on AQR Capital Management's 13F filing for Q1 2021, filed 17 May 2021.